JP2019521087A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521087A5 JP2019521087A5 JP2018559845A JP2018559845A JP2019521087A5 JP 2019521087 A5 JP2019521087 A5 JP 2019521087A5 JP 2018559845 A JP2018559845 A JP 2018559845A JP 2018559845 A JP2018559845 A JP 2018559845A JP 2019521087 A5 JP2019521087 A5 JP 2019521087A5
- Authority
- JP
- Japan
- Prior art keywords
- adc
- administered
- use according
- seq
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000611 antibody drug conjugate Substances 0.000 claims 42
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 42
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 229940121647 egfr inhibitor Drugs 0.000 claims 3
- 238000009097 single-agent therapy Methods 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 claims 3
- 101150105382 MET gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 101150039808 Egfr gene Proteins 0.000 claims 1
- 206010062878 Gastrooesophageal cancer Diseases 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000562 conjugate Substances 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108700021358 erbB-1 Genes Proteins 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000006974 gastroesophageal cancer Diseases 0.000 claims 1
- 201000008443 lung non-squamous non-small cell carcinoma Diseases 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337796P | 2016-05-17 | 2016-05-17 | |
| US62/337,796 | 2016-05-17 | ||
| PCT/US2017/033176 WO2017201204A1 (en) | 2016-05-17 | 2017-05-17 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009320A Division JP6870161B1 (ja) | 2016-05-17 | 2021-01-25 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521087A JP2019521087A (ja) | 2019-07-25 |
| JP2019521087A5 true JP2019521087A5 (OSRAM) | 2021-03-04 |
Family
ID=59014737
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559845A Pending JP2019521087A (ja) | 2016-05-17 | 2017-05-17 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
| JP2021009320A Active JP6870161B1 (ja) | 2016-05-17 | 2021-01-25 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
| JP2021068144A Active JP7150087B2 (ja) | 2016-05-17 | 2021-04-14 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
| JP2022152185A Pending JP2022185003A (ja) | 2016-05-17 | 2022-09-26 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021009320A Active JP6870161B1 (ja) | 2016-05-17 | 2021-01-25 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
| JP2021068144A Active JP7150087B2 (ja) | 2016-05-17 | 2021-04-14 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
| JP2022152185A Pending JP2022185003A (ja) | 2016-05-17 | 2022-09-26 | 抗ｃＭｅｔ抗体薬物複合体及びその使用方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US20170348429A1 (OSRAM) |
| EP (4) | EP4233909A3 (OSRAM) |
| JP (4) | JP2019521087A (OSRAM) |
| KR (3) | KR20230028574A (OSRAM) |
| CN (3) | CN114177308B (OSRAM) |
| AU (1) | AU2017268342B2 (OSRAM) |
| BR (1) | BR112018073574A2 (OSRAM) |
| CA (1) | CA3024386C (OSRAM) |
| CY (2) | CY1123256T1 (OSRAM) |
| DK (2) | DK3626273T3 (OSRAM) |
| ES (2) | ES2864150T3 (OSRAM) |
| HR (2) | HRP20201186T1 (OSRAM) |
| HU (2) | HUE053332T2 (OSRAM) |
| IL (3) | IL262869B (OSRAM) |
| LT (2) | LT3626273T (OSRAM) |
| MX (1) | MX2018014175A (OSRAM) |
| NZ (1) | NZ748314A (OSRAM) |
| PL (2) | PL3458102T3 (OSRAM) |
| PT (2) | PT3458102T (OSRAM) |
| RS (2) | RS60663B1 (OSRAM) |
| RU (1) | RU2740996C2 (OSRAM) |
| SG (2) | SG11201810034XA (OSRAM) |
| SI (2) | SI3458102T1 (OSRAM) |
| SM (2) | SMT202100122T1 (OSRAM) |
| WO (1) | WO2017201204A1 (OSRAM) |
| ZA (1) | ZA201808386B (OSRAM) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230028574A (ko) | 2016-05-17 | 2023-02-28 | 애브비 바이오테라퓨틱스 인크. | 항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 방법 |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| US11167039B2 (en) * | 2016-11-23 | 2021-11-09 | Eli Lilly And Company | MET antibody drug conjugates |
| CN110144325A (zh) * | 2018-02-12 | 2019-08-20 | 深圳宾德生物技术有限公司 | 一种靶向性t淋巴细胞及其制备方法和应用 |
| IL277049B2 (en) | 2018-03-13 | 2024-02-01 | Zymeworks Bc Inc | Conjugates of biparatopic anti-HER2 antibody and drug and methods of use |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| SG11202009308WA (en) * | 2018-03-28 | 2020-10-29 | Mitsubishi Tanabe Pharma Corp | DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF |
| JP7408646B2 (ja) * | 2018-09-30 | 2024-01-05 | ジエンス ハンソー ファーマスーティカル グループ カンパニー リミテッド | 抗－ｂ７ｈ３抗体－エキサテカンアナログコンジュゲート及びその医薬用途 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| KR102353568B1 (ko) * | 2018-11-14 | 2022-01-20 | 주식회사 헬릭스미스 | 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편 |
| AU2020321368A1 (en) * | 2019-07-30 | 2022-03-10 | Mythic Therapeutics, Inc. | Antigen-binding protein constructs and uses thereof |
| KR20220063185A (ko) | 2019-09-16 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질 |
| CN112604004B (zh) * | 2019-09-19 | 2022-05-10 | 中国医学科学院医药生物技术研究所 | 一类抗人egfr抗体药物偶联物及其制备方法与应用 |
| CN110893236A (zh) * | 2019-10-09 | 2020-03-20 | 中山大学 | 溶酶体靶向的抗体药物偶联物及其应用 |
| CN115803009A (zh) | 2020-05-08 | 2023-03-14 | 瑞泽恩制药公司 | 用于治疗眼病和癌症的vegf阱和微阱及方法 |
| CA3161919A1 (en) * | 2020-09-01 | 2022-03-10 | Remegen Co., Ltd. | Anti-c-met antibody-drug conjugate and applications thereof |
| JP2023542301A (ja) * | 2020-09-12 | 2023-10-06 | メディミューン リミテッド | 抗ｂ７ｈ４抗体薬物コンジュゲート療法のためのスコア化方法 |
| CN116472064A (zh) * | 2020-10-12 | 2023-07-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| CN114533891B (zh) * | 2020-11-24 | 2023-04-18 | 深圳先进技术研究院 | 一种靶向无痕释放药物缀合物及其制备方法与应用 |
| FI4288456T3 (fi) | 2021-02-03 | 2024-11-19 | Mythic Therapeutics Inc | Anti-met-vasta-aineita ja niiden käyttöjä |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| BR112023020562A2 (pt) * | 2021-04-06 | 2023-12-05 | Abbvie Biotherapeutics Inc | Métodos de tratamento de carcinoma pulmonar de células não pequenas com o uso de telisotuzumabe vedotina |
| JP2024513244A (ja) | 2021-04-07 | 2024-03-22 | ミシク セラピューティクス， インコーポレイテッド | 抗原結合タンパク質構築物および抗体およびその使用 |
| MX2023011929A (es) | 2021-04-08 | 2023-10-23 | Byondis Bv | Anticuerpos anti-c-met y conjugados de anticuerpo-farmaco. |
| UY39743A (es) | 2021-04-29 | 2022-11-30 | Abbvie Inc | Conjugados de anticuerpo anti-c-met y fármaco |
| AU2022388735A1 (en) | 2021-11-09 | 2024-05-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| CN114369162B (zh) * | 2021-12-28 | 2023-05-30 | 合肥天港免疫药物有限公司 | 抗体及其应用 |
| US20230285394A1 (en) | 2022-03-11 | 2023-09-14 | Abbvie Biotherapeutics Inc. | Methods of treatment of non-small-cell lung carcinoma using telisotuzummab vedotin and osimertinib |
| WO2024065056A1 (en) * | 2022-09-28 | 2024-04-04 | Zymeworks Bc Inc. | Antibody drug conjugates targeting c-met and methods of use |
| KR20250083225A (ko) | 2022-10-12 | 2025-06-09 | 마이틱 테라퓨틱스, 인크. | Lrrc15-결합 단백질 작제물 및 이의 용도 |
| KR20250122502A (ko) | 2022-12-11 | 2025-08-13 | 마이틱 테라퓨틱스, 인크. | 항-cMET 항체 약물 접합체 및 이의 치료적 용도 |
| FI131754B1 (en) * | 2023-03-13 | 2025-11-11 | Glykos Finland Oy | Antibody-exatecan conjugates |
| WO2024240634A1 (en) | 2023-05-19 | 2024-11-28 | Les Laboratoires Servier | Anti-met antibodies, antibody-drug conjugates, compositions and uses thereof |
| WO2025021151A1 (zh) * | 2023-07-25 | 2025-01-30 | 江苏恒瑞医药股份有限公司 | 靶向c-Met的抗体-药物偶联物及其医药用途 |
| WO2025027529A1 (en) | 2023-07-31 | 2025-02-06 | Advesya | Anti-il-1rap antibody drug conjugates and methods of use thereof |
| WO2025078841A2 (en) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Antibodies, conjugates, and uses thereof |
| KR20250057672A (ko) * | 2023-10-19 | 2025-04-29 | (주)셀트리온 | 캄프토테신 유도체를 포함하는 항-c-MET 항체-약물 접합체 |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
| WO2025166213A1 (en) * | 2024-02-01 | 2025-08-07 | Fulgent Pharma Llc | Treatment of head and neck cancer with pharmaceutical composition comprising nanoparticles containing taxane |
| WO2025245128A1 (en) | 2024-05-20 | 2025-11-27 | Mythic Therapeutics, Inc. | Antibody drug conjugates and therapeutic uses thereof |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| BRPI9809391B8 (pt) | 1997-04-14 | 2021-05-25 | Amgen Res Munich Gmbh | processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| JP2002530081A (ja) | 1998-11-18 | 2002-09-17 | ジェネンテック・インコーポレーテッド | 親抗体より高度な結合親和性を持つ抗体変異体 |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| CA2802205C (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| WO2004019993A1 (en) | 2002-08-30 | 2004-03-11 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| CA2506080A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| KR101531400B1 (ko) * | 2003-06-27 | 2015-06-26 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도 |
| NZ583292A (en) * | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| WO2005084390A2 (en) * | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| PT3248613T (pt) | 2005-07-18 | 2022-03-16 | Seagen Inc | Conjugados de ligante de fármaco e beta-glucuronida |
| BRPI0707426A2 (pt) | 2006-02-02 | 2011-05-03 | Syntarga Bv | composto, conjugado, uso de um composto, composição farmacêutica, processo para preparar uma composição farmacêutica, e, métodos de tratamento de um mamìfero estando em necessidade do mesmo, e de tratamento ou prevenção de um tumor em um mamìfero |
| ES2523915T5 (es) | 2006-12-01 | 2022-05-26 | Seagen Inc | Agentes de unión a la diana variantes y usos de los mismos |
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| JP5557746B2 (ja) | 2007-11-28 | 2014-07-23 | メルサナ セラピューティックス，インク． | 生体適合性生分解性フマギリンアナログ複合体 |
| US20140112911A9 (en) | 2008-12-02 | 2014-04-24 | Liliane Goetsch | Novel anti-cmet antibody |
| US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| US20100152725A1 (en) | 2008-12-12 | 2010-06-17 | Angiodynamics, Inc. | Method and system for tissue treatment utilizing irreversible electroporation and thermal track coagulation |
| US8524214B2 (en) | 2009-05-28 | 2013-09-03 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| EP2287197A1 (en) | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| WO2011071020A1 (ja) | 2009-12-07 | 2011-06-16 | 株式会社エヌ・ティ・ティ・ドコモ | 伝搬経路推定方法、プログラム及び装置 |
| US20130004616A1 (en) | 2010-03-10 | 2013-01-03 | Novartis Ag | Streptococcus thermophilus bacterium |
| WO2011120053A1 (en) | 2010-03-26 | 2011-09-29 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| DE102010012915A1 (de) | 2010-03-26 | 2011-09-29 | Schaeffler Technologies Gmbh & Co. Kg | Vorrichtung und Verfahren zur Ermittlung eines Schädigungszustands eines Radlagers |
| EP2402370A1 (en) | 2010-06-29 | 2012-01-04 | Pierre Fabre Médicament | Novel antibody for the diagnosis and/or prognosis of cancer |
| BR122020001787A8 (pt) * | 2011-05-08 | 2023-04-25 | Legochem Biosciences Inc | Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso |
| KR101972303B1 (ko) | 2011-06-10 | 2019-04-25 | 메르사나 테라퓨틱스, 인코포레이티드 | 단백질-중합체-약물 접합체 |
| KR101463098B1 (ko) * | 2011-11-28 | 2014-11-27 | 한국생명공학연구원 | ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도 |
| BR112014013526A8 (pt) | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| TW201332574A (zh) | 2011-12-23 | 2013-08-16 | Mersana Therapeutics Inc | 煙曲黴素衍生物－ｐｈｆ共軛物之醫藥調配物 |
| EP2818480B1 (en) * | 2012-02-24 | 2020-08-26 | Alteogen Inc. | Modified antibody in which motif comprising cysteine residue is bound, modified antibody-drug conjugate comprising the modified antibody, and production method for same |
| US9504756B2 (en) | 2012-05-15 | 2016-11-29 | Seattle Genetics, Inc. | Self-stabilizing linker conjugates |
| US20140017265A1 (en) | 2012-07-05 | 2014-01-16 | Mersana Therapeutics, Inc. | Terminally Modified Polymers and Conjugates Thereof |
| US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| EP2928504B1 (en) | 2012-12-10 | 2019-02-20 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| US9872918B2 (en) | 2012-12-12 | 2018-01-23 | Mersana Therapeutics, Inc. | Hydroxyl-polymer-drug-protein conjugates |
| HRP20190672T1 (hr) * | 2013-03-15 | 2019-08-23 | AbbVie Deutschland GmbH & Co. KG | Konjugirane formulacije anti-egfr protutijelo-lijek |
| KR102150616B1 (ko) * | 2013-09-12 | 2020-09-03 | 삼성전자주식회사 | c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도 |
| WO2016042412A1 (en) | 2014-09-16 | 2016-03-24 | Symphogen A/S | Anti-met antibodies and compositions |
| WO2016165580A1 (zh) * | 2015-04-17 | 2016-10-20 | 江苏恒瑞医药股份有限公司 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
| CN106188293A (zh) * | 2015-04-17 | 2016-12-07 | 江苏恒瑞医药股份有限公司 | 抗c-Met抗体和抗c-Met抗体-细胞毒性药物偶联物及其医药用途 |
| KR20230028574A (ko) * | 2016-05-17 | 2023-02-28 | 애브비 바이오테라퓨틱스 인크. | 항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 방법 |
-
2017
- 2017-05-17 KR KR1020237005212A patent/KR20230028574A/ko not_active Withdrawn
- 2017-05-17 HR HRP20201186TT patent/HRP20201186T1/hr unknown
- 2017-05-17 HU HUE19197371A patent/HUE053332T2/hu unknown
- 2017-05-17 KR KR1020187036427A patent/KR102449294B1/ko active Active
- 2017-05-17 ES ES19197371T patent/ES2864150T3/es active Active
- 2017-05-17 BR BR112018073574-4A patent/BR112018073574A2/pt unknown
- 2017-05-17 RS RS20200927A patent/RS60663B1/sr unknown
- 2017-05-17 CN CN202111566314.4A patent/CN114177308B/zh active Active
- 2017-05-17 ES ES17728311T patent/ES2811351T3/es active Active
- 2017-05-17 SI SI201730337T patent/SI3458102T1/sl unknown
- 2017-05-17 MX MX2018014175A patent/MX2018014175A/es unknown
- 2017-05-17 EP EP23163423.9A patent/EP4233909A3/en active Pending
- 2017-05-17 AU AU2017268342A patent/AU2017268342B2/en active Active
- 2017-05-17 US US15/597,624 patent/US20170348429A1/en not_active Abandoned
- 2017-05-17 IL IL262869A patent/IL262869B/en unknown
- 2017-05-17 EP EP19197371.8A patent/EP3626273B1/en active Active
- 2017-05-17 HU HUE17728311A patent/HUE050398T2/hu unknown
- 2017-05-17 NZ NZ748314A patent/NZ748314A/en unknown
- 2017-05-17 PT PT177283116T patent/PT3458102T/pt unknown
- 2017-05-17 RS RS20210246A patent/RS61659B1/sr unknown
- 2017-05-17 SM SM20210122T patent/SMT202100122T1/it unknown
- 2017-05-17 PL PL17728311T patent/PL3458102T3/pl unknown
- 2017-05-17 DK DK19197371.8T patent/DK3626273T3/da active
- 2017-05-17 SG SG11201810034XA patent/SG11201810034XA/en unknown
- 2017-05-17 PL PL19197371T patent/PL3626273T3/pl unknown
- 2017-05-17 DK DK17728311.6T patent/DK3458102T3/da active
- 2017-05-17 JP JP2018559845A patent/JP2019521087A/ja active Pending
- 2017-05-17 SG SG10201914095SA patent/SG10201914095SA/en unknown
- 2017-05-17 LT LTEP19197371.8T patent/LT3626273T/lt unknown
- 2017-05-17 EP EP17728311.6A patent/EP3458102B1/en active Active
- 2017-05-17 SI SI201730649T patent/SI3626273T1/sl unknown
- 2017-05-17 SM SM20200467T patent/SMT202000467T1/it unknown
- 2017-05-17 EP EP20208371.3A patent/EP3804765A1/en not_active Withdrawn
- 2017-05-17 WO PCT/US2017/033176 patent/WO2017201204A1/en not_active Ceased
- 2017-05-17 KR KR1020227033500A patent/KR102512597B1/ko active Active
- 2017-05-17 PT PT191973718T patent/PT3626273T/pt unknown
- 2017-05-17 RU RU2018144315A patent/RU2740996C2/ru active
- 2017-05-17 CN CN202111593727.1A patent/CN114246953B/zh active Active
- 2017-05-17 LT LTEP17728311.6T patent/LT3458102T/lt unknown
- 2017-05-17 CA CA3024386A patent/CA3024386C/en active Active
- 2017-05-17 CN CN201780044009.4A patent/CN109562189B/zh active Active
- 2017-05-17 IL IL294146A patent/IL294146B2/en unknown
-
2018
- 2018-03-02 US US15/910,788 patent/US10383948B2/en active Active
- 2018-12-12 ZA ZA2018/08386A patent/ZA201808386B/en unknown
-
2019
- 2019-05-28 US US16/424,324 patent/US10603389B2/en active Active
-
2020
- 2020-01-17 US US16/746,497 patent/US20200215200A1/en active Pending
- 2020-08-10 CY CY20201100742T patent/CY1123256T1/el unknown
-
2021
- 2021-01-25 JP JP2021009320A patent/JP6870161B1/ja active Active
- 2021-02-25 HR HRP20210326TT patent/HRP20210326T1/hr unknown
- 2021-03-01 CY CY20211100168T patent/CY1123858T1/el unknown
- 2021-04-14 JP JP2021068144A patent/JP7150087B2/ja active Active
-
2022
- 2022-09-26 JP JP2022152185A patent/JP2022185003A/ja active Pending
-
2023
- 2023-02-22 US US18/172,769 patent/US20230321271A1/en not_active Abandoned
- 2023-07-25 IL IL304717A patent/IL304717A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019521087A5 (OSRAM) | ||
| Paoluzzi et al. | Response to anti-PD1 therapy with nivolumab in metastatic sarcomas | |
| JP2020527572A5 (OSRAM) | ||
| TW202038957A (zh) | 抗體-藥物結合物與激酶抑制劑之組合 | |
| JP2015534577A5 (OSRAM) | ||
| JP2020535173A5 (OSRAM) | ||
| JP2019506403A5 (OSRAM) | ||
| JP2020508317A5 (OSRAM) | ||
| JP2014533279A5 (OSRAM) | ||
| JP2007515469A5 (OSRAM) | ||
| JP2019532051A5 (OSRAM) | ||
| JP2012229273A (ja) | ５−ｆｕおよび５−ｆｕプロドラッグと併用してｄｐｄ阻害物質を投与するための方法 | |
| TWI762784B (zh) | Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途 | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023542093A (ja) | 抗腫瘍治療におけるチアウラニブと免疫チェックポイント阻害剤との組み合わせの使用 | |
| JP2019524713A5 (OSRAM) | ||
| TW201127384A (en) | Therapeutic combination comprising a Cdc7 inhibitor and an antineoplastic agent | |
| CN104159589A (zh) | 肝脏状况的治疗 | |
| Reck et al. | Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study | |
| CN115485298A (zh) | 用于治疗癌症的egfr抑制剂和ror1抑制剂的组合 | |
| JPWO2020229626A5 (OSRAM) | ||
| JP2019516728A (ja) | 抗がん組合せ治療 | |
| US20190276439A1 (en) | Method of treating solid tumors | |
| Choi et al. | Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer |